Compare · NMTC vs WST
NMTC vs WST
Side-by-side comparison of NeuroOne Medical Technologies Corporation (NMTC) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NMTC and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $29.10B, about 4289.7x NMTC ($6.8M).
- WST has been more active in the news (6 items in the past 4 weeks vs 1 for NMTC).
- WST has more recent analyst coverage (20 ratings vs 4 for NMTC).
- Company
- NeuroOne Medical Technologies Corporation
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $6.8M
- $29.10B
- 1M return
- -
- +8.80%
- 1Y return
- -
- +59.04%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 6
- Recent ratings
- 4
- 20
NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corporation operates as a medical technology company. It focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and other related brain related disorders. NeuroOne Medical Technologies Corporation has a strategic partnership with RBC Medical Innovations to develop and manufacture a radiofrequency generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest NMTC
- NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation System
- NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program
- NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology
- NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
- NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement
- Chief Business Officer Wambeke David J. bought $66,999 worth of shares (33,333 units at $2.01), increasing direct ownership by 20% to 199,999 units (SEC Form 4)
- SEC Form 4 filed by Chief Administrative Officer Johns Emily J.
- SEC Form 4 filed by Chief Financial Officer Volker Christopher
- SEC Form 4 filed by Market Development Director Christianson Mark
Latest WST
- Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.
- West to Participate in Upcoming Investor Conference
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- SEC Form 8-K filed by West Pharmaceutical Services Inc.
- West Reports Third-Quarter 2026 Results
- SEC Form 8-K filed by West Pharmaceutical Services Inc.
- West Declares Quarterly Dividend
- West to Host Third-Quarter 2026 Conference Call
- West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
- SEC Form 4 filed by Director Haugen Janet Brutschea